Related keylists
View morePfizer Inc (Pfizer) discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.
Headquarters
United States of America
Address
66 Hudson Boulevard East, New York, 10001-2192
Website
www.pfizer.com
Telephone
1 212 7332323
No of Employees
83,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PFE (NYSE)
Revenue (2022)
$100.3B
23.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
42.7%
(2022 vs 2021)
Market Cap*
$181.2B
Net Profit Margin (2022)
XYZ
15.6%
(2022 vs 2021)
* As of and is in US$
Pfizer Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Therapy Areas: | - | Celebrex |
| Internal Medicine | Active Pharmaceutical Ingredients | Eliquis |
| Oncology | Contract Manufacturing | Enbrel |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In September, Pfizer Canada and BioNTech secured an authorization from the Health Canada for Omicron XBB.1.5-adapted monovalent COVID-19 vaccine for ages 6 months and older. |
| 2023 | Contracts/Agreements | In September, the company announced a collaboration with Ginkgo Bioworks to leverage Ginkgo's proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas. |
| 2023 | Regulatory Approval | In September, the company secured marketing authorisation from the European Commission for LITFULO (ritlecitinib) for the treatment of adults and adolescents aged 12 years and above with severe alopecia areata. |
Competitor Comparison
| Key Parameters | Pfizer Inc | Johnson & Johnson | F. Hoffmann-La Roche Ltd | Merck & Co Inc | AbbVie Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United States of America | United States of America |
| City | New York | New Brunswick | Basel | Kenilworth | North Chicago |
| State/Province | New York | New Jersey | - | New Jersey | Illinois |
| No. of Employees | 83,000 | 152,700 | 103,613 | 69,000 | 50,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Albert Bourla, Ph.D. | Chairman; Chief Executive Officer | Executive Board | 2020 | 61 |
| David M. Denton | Executive Vice President; Chief Financial Officer | Senior Management | 2022 | 57 |
| Rady A. Johnson | Chief Compliance Officer; Chief Quality & Risk Officer; Executive Vice President | Senior Management | 2019 | 61 |
| Mikael Dolsten, M.D., Ph.D. | President - Research and Development; Chief Scientific Officer | Senior Management | 2019 | 64 |
| Angela Hwang | President - Global Biopharmaceuticals Business; Chief Commercial Officer | Senior Management | 2022 | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward